EA Series Trust Strive U.S. Energy ETF (NYSE: DRLL)

Últimas noticias sobre EA Series Trust Strive U.S. Energy ETF (NYSE:DRLL)

EA Series Trust Strive U.S. Energy ETF

Energy

Consumer Cyclical

Financial Services

The Fund seeks to track the investment results of the Solactive United States Energy Regulated Capped Index (the Index), which measures the performance of the energy sector of the U.S. equity market as defined by Solactive AG (the Index Provider or Solactive). The Index includes large, and mid-capitalization companies. The Index is a subset of a float-adjusted capitalization weighted index of equity securities comprising the 1,000 largest companies from the US stock market. The Index uses a capping methodology to constrain individual securities at quarterly rebalance to ensure: (i) the weights of any single issuer shall not exceed 22.5 percent, and (ii) the aggregate weight of all issuers that individually exceed 4.5 percent of the Index shall not have a weight greater than 45 percent of the Index. The weight of one or more securities in the Index may exceed these limits due to fluctuations in market value of the securities in the Index, corporate actions, or other events that change the Index composition between quarterly rebalance dates.

Exxon Mobil Corp

Chevron Corp New

Conocophillips Co

Marathon Pete Corp

Eog Resources Inc

Schlumberger Nv.

Phillips 66

Pioneer Nat. Res

Valero Energy Corp

Occidental Pete Corp

Hess Corp.

Diamondback Energy Inc.

Eqt Corp

Strive US Energy ETF

Earnings

Equities

Large Cap

News

Guidance

Dividends

Movers

General

DRLL

Acciones de Chevron bajan tras un débil informe del cuarto trimestre. Pese a ingresos sólidos, las ganancias y el flujo de caja se reducen.

Chevron (CVX) cae tras reportar resultados: menores ganancias y flujo de caja en 2024

Rosenblatt analyst Steve Frankel maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Buy and maintains $11 price target.

Price Target

Analyst Ratings

HLIT

Rosenblatt Maintains Buy on Harmonic, Maintains $11 Price Target

Jabil Raises FY2025 Adj EPS Guidance from $8.95 to $9.33 vs $8.97 Est; Raises FY2025 Sales Guidance from $27.90B to $29.00B vs $28.00B Est

UBS analyst Ashwani Verma upgrades Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) from Neutral to Buy and raises the price target from $33 to $42.

Upgrades

ALKS

UBS Upgrades Alkermes to Buy, Raises Price Target to $42

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) (FSE: 49Q) (BMV:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#BMV">ZENA</a>) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces the launch of the ZenaDrone's IQ Nano, a compact autonomous indoor drone, for US Department of Defense (DoD) agencies and government use to innovate applications including inventory management, facility security, and search and rescue. Following recent <a href="https://www.globenewswire.com/Tracker?data=GTUlvrD-TMKJ_r5f5m8DhCZQDeuOngkYC2A-4ZxZzbF3lMzkNirW9fit8P3xTVCX3b59XFAznXDHHMQv3QqXOzgxAmnyiRMnfVxNJP678xBVS9D0_P9ImgZGAGF1KxcMa0sGKZwbGjUvi6Y7aUsRRAtFbDxZj8uthHDOljv4HN5BQwMcI7DT-zXR_I06UFt2">US Executive Order</a> policy directives aimed at fast-tracking DoD adoption of secure US-made drones and streamlining procurement, the company plans to apply for Green UAS (Unmanned Aerial System) certification, followed by Blue UAS certification required to be officially recognized as a secure and mission-ready drone supplier to US military customers.

BMV:ZENA

ZENA

ZenaTech Launches ZenaDone's IQ Nano For US DoD Agencies And Government Use To Update Applications Including Inventory Management, Facility Security, And Search And Rescue

Jabil Sees Q4 Adj EPS $2.64-$3.04 vs $2.74 Est; Sees Sales $7.100B-$7.800B vs $7.19B Est

WIIM

Jabil shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

Scotiabank analyst Andres Coello downgrades Millicom Intl Cellular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGO#NASDAQ">TIGO</a>) from Sector Outperform to Sector Perform and announces $37 price target.

Downgrades

TIGO

Scotiabank Downgrades Millicom Intl Cellular to Sector Perform, Announces $37 Price Target

Earnings Beats

Jabil Q3 Adj. EPS $2.55 Beats $2.31 Estimate, Sales $7.83B Beat $7.06B Estimate

Turner has served as Yum! Brands' Chief Financial Officer since 2019 and expanded his role to include Chief Franchise Officer in 2024, with responsibilities for finance, corporate strategy, supply chain, franchise standards and support. In recent years, he has been instrumental in driving bold actions that leverage Yum!'s scale, such as accelerating the Company's digital and technology transformation through initiatives like the establishment of Byte by Yum!, an AI-driven restaurant technology platform; launching a centralized, global Supply Chain Center of Excellence; and the creation of Saucy by KFC, a bold new restaurant concept.

Yum! Brands Names Chris Turner As CEO Effective Oct. 1, 2025; Turner Will Succeed Current CEO David Gibbs, Who, In March 2025, Informed His Intention To Retire In The Next Year

Citigroup analyst Geoff Meacham initiates coverage on Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy rating and announces Price Target of $72.

Initiation

PTGX

Citigroup Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $72

Citigroup analyst Geoff Meacham initiates coverage on NewAmsterdam Pharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) with a Buy rating and announces Price Target of $42.

NAMS

Citigroup Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $42

Citigroup analyst Geoff Meacham initiates coverage on Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Buy rating and announces Price Target of $110.

ACLX

Citigroup Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $110

Citigroup analyst Geoff Meacham initiates coverage on Amylyx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) with a Buy rating and announces Price Target of $12.

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Citigroup Initiates Coverage On Amylyx Pharmaceuticals with Buy Rating, Announces Price Target of $12

Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces entering into a 50:50 joint venture with Mind Medicine Australia ("MMA") to operate a psychedelic-assisted therapies services clinic in Melbourne.
Incannex CEO Joel Latham commented, "This joint venture is a significant milestone around our strategy to bring psychedelic-assisted therapies to those who need them most. Working alongside a leading organization in this space, we expect to build the clinical infrastructure necessary to deliver safe, effective, and scalable treatment options. Importantly, this initiative not only strengthens our presence in a high-growth therapeutic sector but also aligns with our long-term commitment to generating opportunities for sustainable long-term shareholder value."
The new entity, Mind Medicine Australia Clinics, represents a strategic advancement in Incannex's commercialization model. The joint venture will deliver a fully integrated suite of services including clinical operations, governance, medicine supply, medical oversight, and marketing support to a growing network of aligned Authorised Prescribers across Australia.
Mind Medicine Australia Chairman Peter Hunt commented, "This groundbreaking initiative in partnership with Incannex brings critical resources and clinical expertise that will enhance the quality, accessibility, and scale of these transformative treatments. Our new clinic will serve as a Centre of Excellence, delivering best-in-class care and clinician training."
The updated clinic model will significantly expand treatment access by reducing the cost of entry and more than tripling capacity. These improvements are expected to benefit individuals suffering from post-traumatic stress disorder (PTSD), treatment-resistant depression, and other complex mental health conditions. Patient intake is expected to begin shortly in response to strong early demand.

IXHL

Incannex Launches Psychedelic Therapy Clinic in Australia to Expand Mental Health Treatment Access

Unlike one-dimensional AI agents, Mpower Agents are uniquely built to work across the entire enterprise – front, middle and back office – to automate complete journeys, not just conversations
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nice.com&amp;esheet=54276733&amp;newsitemid=20250617282648&amp;lan=en-US&amp;anchor=NiCE&amp;index=1&amp;md5=cbe08caca9865354f914dbea1223a7d9">NiCE</a> (NASDAQ:<a href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) today announced the launch of CXone Mpower Agents, a groundbreaking innovation that enables fully automated, AI agents to be created and deployed in seconds and immediately work across the customer service ecosystem – from self-service to mid-office approvals to back-end fulfillment. Mpower Agents make use of CXone Mpower's proprietary CX AI models, trained on rich use case-specific data and optimized workflows based on the actions of the best employees. They actively move across systems, trigger actions and work together with humans and other AI agents to automate entire service workflows.

NICE

NiCE Launches CXone Mpower Agents, Enabling Instant AI Deployment Across Customer Service

Needham analyst Laura Martin reiterates DoubleVerify Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Buy and maintains $18 price target.

Reiteration

Needham Reiterates Buy on DoubleVerify Holdings, Maintains $18 Price Target

Citigroup analyst Geoff Meacham initiates coverage on Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) with a Buy rating and announces Price Target of $4.

ABOS

Citigroup Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $4

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States
Study shows &gt;95% success rate, validating BE-Smart for use with esophageal brush cytology.
ProPhase Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced the successful completion of a key validation study evaluating the performance of the BE-Smart&#x2122; molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart&#x2122; achieved greater than a 95% technical success rate, confirming the BE-Smart's ability to reliably and accurately detect our panel of biomarkers, designed to assess progression risk in Barrett's esophagus and other distal esophageal conditions. Prophase will now move to accelerated commercialization of BE-Smart&#x2122; with expected clinical launch in the next 2-3 quarters.
BE-Smart uses a proprietary panel of biomarkers and a multi-modal analysis method which together significantly increase detection of deadly cancer cells in one of the fastest growing cancer indications, esophageal denocarcinoma cancer or "EAC". EAC has a 5-year mortality rate of over 79% and surged in annual incidence over 750% since the 1970s. BE-Smart represents a technical advance in detection and prognosis which has the potential to change cost and outcomes for the large population affected by GERD, Barrett's and EAC globally.

PRPH

ProPhase Labs Validates BE-Smart Test; Study Demonstrates High Accuracy; Clinical Rollout Expected Within 2-3 Quarters

<a href="https://pr.report/bkw9">SideChannel, Inc.</a> (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/SDCH#OTCQB">SDCH</a>) ("SideChannel"), a leader in modern cybersecurity technology and services solutions, today announced the deployment of its Enclave zero trust software by a second service branch of the United States Department of Defense ("DoD"). The engagement, facilitated through one of SideChannel's federal resale partners, represents a key validation of Enclave's ability to meet the large scale and strict cybersecurity needs of national security environments.
The deployment includes over 5,000 Enclave agents operating on-premise within national intelligence networks. The primary use cases are asset intelligence and certificate management - two critical areas for maintaining integrity and security control in sensitive infrastructure.

Comments

EA Series Trust Strive U.S. Energy ETF

Noticias

Últimas noticias sobre EA Series Trust Strive U.S. Energy ETF (NYSE:DRLL)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL